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Abstract
Purpose To evaluate the correlation between change in
FDG uptake before and after chemotherapy in hepatic
metastases of colorectal carcinoma (HCRC) and a histo-
pathologic tumor regression grade (TRG).
Methods In patients with HCRC, PET/CT data prior
to hepatic surgery were retrospectively analyzed under
an IRB waiver. The maximum standard uptake value
(SUVmax) was measured before and after chemotherapy.
The relative change of FDG activity in the identified
lesions was calculated (dSUV). Histopathological speci-
mens of resected metastases were graded on a 5-score TRG
scale. A TRG of 1–3 was rated as a responding to therapy,
whereas TRG 4–5 were regarded as non-responding
lesions.
Results 31 lesions were identified in 23 patients. Mean
SUVmax before and after therapy was 6.9 ± 3.7 and
3.5 ± 1.8, respectively. The area under the receiver oper-
ator characteristic curve revealed a conclusive correlation
between TRG and dSUV (AUC 0.773; 95 % confidence
interval 0.599–0.946) with a cut off at 41 % decrease in
FDG activity yielding a sensitivity and specificity of 72 and
75 %, respectively.
Conclusion A relative change in FDG activity (dSUV) of
more than 41 % decrease correlated significantly with
histopathological tumor regression and might be a prog-
nostic tool for response to chemotherapy in HCRC.
Keywords FDG PET/CT  Tumor regression grade 
Colorectal cancer  Hepatic metastasis  Therapy response
assessment
Introduction
In the past decades the use of neoadjuvant chemotherapy
before surgery for hepatic metastasis of colorectal carci-
noma (HCRC) gained significance [1]. Thanks to the
introduction of more effective chemotherapeutic agents
and targeted agents for HCRC this approach improved the
outcome [2]. The main intention thereby is to render pri-
marily unresectable patients resectable [3, 4]. To determine
the eligibility of patients preoperative 18F-fluorodeoxy-
glucose (FDG) PET/CT has shown to reduce futile lapa-
rotomies since not only the liver but the entire body is
evaluated and distant recurrences or progression can be
detected [5].
Metabolic alterations in tumor cells have been shown to
occur before alterations in tumor size and might be a better
indicative of tumor response to therapy [6]. Therefore, the
preoperative FDG PET/CT scan has also been used for
therapy response assessment [7]. For evaluation of tumor
response with FDG PET, the European Organization for
Research and Treatment of Cancer (EORTC) released a
widely accepted standardization in 1999 [8]. However,
since then different percentages of relative change in FDG
uptake have been suggested, to distinguish complete or
partial remission from stable or progressive disease.
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EORTC guidelines suggested a partial remission with
[15 % decrease in SUV after one cycle of chemotherapy,
or [25 % decrease after more than one cycle [8], others a
decrease of [30 % for partial remission [9].
These generalized guidelines for all solid tumor entities
lack pathological correlates and cannot take variable bio-
logical tumor behaviour into account. Therefore, a correla-
tion of the change in FDG measured as the relative change in
SUVmax with histopathological tumor regression grades
(TRGs) for specific tumor types has been suggested [10–13].
These studies showed that for locally advanced rectal cancer a
decrease between 53 and 66 % in FDG activity correlated
well with a good pathological response to chemo radiation
therapy [10, 13]. On the other hand, the correlation between
decrease in FDG uptake and histopathological response in
esophageal carcinomas was not significant [11, 12, 14].
Histopathological analysis of residual tumor viability with
a TRG was initially proposed for rectal cancer, reaching from
Grade 1 with complete fibrosis to Grade 5 with complete
absence of regressive changes [15]. A modified version of this
TRG scoring system has been suggested to assess the therapy
response in HCRC [16]. With this score TRG responders had
a significantly improved disease-free survival (DFS) and
overall survival (OS) [16].
To our knowledge no previous study investigated the
correlation between TRG, and the relative change in FDG
uptake before and after chemotherapy for HCRC. The aim
of our analysis was to correlate the relative change in FDG
uptake with TRG and to determine the optimal cut off to
distinguish histopathological responders from non-
responders with FDG PET/CT.
Materials and methods
Patients
We consecutively screened all patients between June 2007
and July 2010 with colorectal carcinoma referred from the
visceral surgery department to the division of nuclear medi-
cine and selected those patients with HCRC who underwent
FDG PET/CT before and after chemotherapy. Patients were
eligible if the second FDG PET/CT was within 2–7 weeks
after last chemotherapy. 69 patients met the inclusion criteria.
3 patients had partial liver resection between both scans and 2
patients had one FDG PET/CT examination in a different
institution and were therefore excluded. Of the remaining 64
patients, 42 had surgery with resection of hepatic metastases
within 8 weeks after FDG PET/CT [17, 18]. From the med-
ical records, a clear correlation between pathology and FDG
PET/CT was possible for 31 lesions (max 3 lesions per
patient) in 23 patients (Fig. 1).
PET/CT acquisition and analysis
All patients were examined using a routine clinical proto-
col on dedicated PET/CT scanners (GE Healthcare DSTX,
16- or 64-slices CT, 7–8 frames, frame time 1.5 or 2 min)
with injection of 350 MBq FDG 45–60 min before exam-
ination. A low dose unenhanced CT-scan was performed
for attenuation correction and used for anatomical locali-
zation (80 mA, 140 kV). Approximate total dose equiva-
lent for the entire PET/CT examination =10 mSv. To
reduce bladder activity patients had to urinate just before
image acquisition [19].
Image analysis was performed by a dual board certified
nuclear medicine physician and radiologist (TFH), blinded
for the results from histopathology. The activity in the
identified lesions was measured as the maximum value in a
volume of interest (VOI) around the whole selected lesion.
The relative change in FDG activity between the two PET/
CT scans before and after neo-adjuvant (for resectable
patients) or downstaging (for unresectable patients) che-
motherapy was calculated (dSUV), Eq (1):
dSUVð%Þ ¼ SUVmaxðscan 2Þ  SUVmaxðscan 1Þ
SUVmaxðscan 1Þ  100:
ð1Þ
Fig. 1 Flow chart illustrating the eligibility criteria for patient and
lesion selection
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Histopathological analysis
Histopathological specimens of resected metastases were
evaluated for the proportion of viable tumor cells, tumor
necrosis, and fibrosis in Hematoxylin and Eosin staining.
TRG was graded on a 5-point scale based on the histo-
logical tumor response assessment described by Rubbia-
Brandt et al. [16]. TRG 1 signifies complete tumor
regression showing only fibrosis as sign of regression and
no residual cancer in the former metastasis. The amount
of viable tumor cells increases with TRG whereas the
extent of fibrosis decreases with complete absence in
TRG 5.
Statistical analysis
The distribution of dSUV values for each histopathological
TRG was analyzed using box plots. Correlation between
TRG and dSUV was calculated with Pearson correlation. A
receiver operator characteristic (ROC) curve was generated
for dSUV and TRG responders versus non-responders. The
area under the curve (AUC) was calculated and the optimal
cut off point for the ROC curve determined using the
Youden index (J value), calculated as the maximum of
J = SN ? SP - 1, where SN is sensitivity and SP is
specificity, for each cut off volume [20].
Results
31 resected liver lesions were identified in 23 patients. 19
of 23 patients were treated with folic acid and fluorouracil
combined with either oxaliplatin or irinotecan. 4 patients
were treated with fluorouracil and optional bevacizumab or
oxaliplatin. Demographic details are listed in Table 1.
In the baseline study the HCRC had SUVmax values of
7.4 ± 3.7 (range 2.9–15.3). The SUVmax for all lesions in
the second scan was 3.5 ± 2.1 (range 1.6–12).
The histopathological analysis revealed complete fibro-
sis in 2 lesions (TRG 1), more fibrosis than residual viable
tumor in 18 lesions (TRG 2 and 3) and more viable tumor
than fibrosis in 11 lesions (TRG 4 and 5) (Table 2).
The relative change in SUVmax for the five histological
TRG grades is given in Fig. 2 with box plots. The corre-
lation between TRG and dSUV was significant (correlation
r = 0.48, p = 0.001, 2-tailed). The ROC curve revealed an
AUC of 0.773 (95 % confidence interval 0.599–0.946),
with an optimal cut off to distinguish responders from
non-responders of dSUV -41 %, yielding a sensitivity,
specificity, positive and negative predictive value and an
accuracy of 72, 75, 83, 62 and 74 %, respectively (Fig. 3).
With a cut off at dSUV -41 %, 15 lesions were
regarded responding in FDG PET/CT CT and also histo-
pathological responders (TRG 1–3). Figure 4 is an example
of complete remission in PET/CT with no residual FDG
uptake and a complete histological tumor regression (TRG
1). 13 lesions were non-responders in FDG PET/CT, his-
topathology however revealed response to therapy in 5 of
these lesions (all lesions TRG 3). The mean dSUV overall
was -41 ± 42 % (range -89.5 to 126 %). All lesions with
Table 1 Patient demographics
Number of patients 23
Age (years ± SD) 57.2 ± 8
Gender (male/female) (14/9)
Lesions identified 31
Time delay between
Chemotherapy and PET/CT II (days ± SD) 25.3 ± 21.7
PET/CT II and surgery (days ± SD) 27.6 ± 25.7
Chemotherapy regimens (patients)
FOLFOX 12
FOLFIRI (? optional Bevacizumab) 7
5-FU (? optional Bevacizumab or oxaliplatin) 4
Chemotherapy intention
Neo-adjuvant 11
Down staging 12
Standard deviation (SD), folic acid–fluorouracil–oxaliplatin (FOL-
FOX), folic acid–fluorouracil–irinotecan (FOLFIRI), fluorouracil
(5-FU)
Table 2 FDG PET/CT values:
pre- and post-chemotherapy
SD standard deviation
TRG Responding lesions Non-responding lesions
1 2 3 4 5
Number of lesions 2 4 14 9 2
SUV PET I (mean ± SD) 14.1 ± 1.7 9.1 ± 4.2 7.3 ± 3.6 5.9 ± 2.5 5.1 ± 0.3
SUV PET II (mean ± SD) 2.1 ± 0.7 2.8 ± 0.9 3.0 ± 0.8 3.7 ± 2.0 9.1 ± 4.1
dSUV (mean ± SD %) -84.7 ± 6.9 -66.8 ± 12.5 -48.6 ± 24.5 -32.4 ± 29.1 76 ± 70
With cut off (-41 %) PET
responding/non-resp.
2/0 4/0 9/5 3/6 0/2
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an increase in dSUV showed no signs of histopathological
response (TRG 4 or 5) (Table 3). Figure 5 illustrates a case
of increased FDG uptake in the second PET/CT, corre-
sponding to a high degree of remaining vital tumor cells
analogous to TRG 5. In one lesion PET/CT suggested
therapy response (dSUV) -76 %; histopathology revealed
a mixed image with areas of extended necrosis (Fig. 6C1),
and areas of more vital cells than fibrosis (TRG 4,
Fig. 6C2).
For six patients two lesions were included in the study,
of those two patients had a decrease in dSUV of less than
41 % in both lesions and were regarded as non-responders,
whereas four patients decreased more than 41 % in both
lesions. In one patient 3 lesions could be identified on PET/
CT and pathology reports and were included in the study:
two lesions decreased less than 41 % and one lesion
decreased 51 % between the two PET/CT scans, resulting
in a mixed response.
Discussion
The objective of this study was to assess the diagnostic
accuracy of response assessment with FDG PET/CT in
patients with HCRC treated with neoadjuvant chemother-
apy by correlating change in FDG uptake with histopa-
thological tumor response.
Overall, change in FDG activity in HCRC after che-
motherapy correlated significant with overall survival in
several studies and FDG PET seems to be a reliable
prognostic tool to predict the efficacy of preoperative
chemotherapy [18, 21].
Previous recommendations for therapy assessment with
FDG PET/CT suggested a decrease of 15–30 % for a partial
metabolic response [8, 9]. In the present study a significant
correlation between FDG uptake and the TRG system for
HCRC was found (p = 0.001). A cut off at -41 % dSUV for
responding lesions could be identified resulting in a positive
predictive value of over 83 %. Therefore, similar to the
results for locally advanced rectal cancer the requested
decrease in SUVmax after neoadjuvant chemotherapy might
be higher for HCRC than the currently generally recom-
mended 15–30 % to reflect histopathological tumor regres-
sion [10, 13]. This underlines the need to determine
PET-response criteria individually for each cancer entity as it
has been demonstrated for esophageal cancer as well [11, 12].
Furthermore, an increase in dSUV was predictive for histo-
pathological non-response in all cases.
FDG PET/CT cannot replace a histopathological work
up after tumor resection. However, preoperative FDG PET
has shown to detect distant recurrences and is therefore an
efficient tool in the selection of resectable patients after
neo-adjuvant chemotherapy [5]. Additionally, reliable non-
invasive assessment of treatment efficacy can be helpful for
the oncologist for further treatment planning of the
patients, since the same chemotherapy regimen can be
continued, e.g., in difficult surgical situations when com-
plete resection in a single step procedure is not possible or
for completion of neo-adjuvant treatment.
Fig. 2 Box plot illustration of the distribution of dSUV for the 5
different TRG groups
Fig. 3 Receiver operating characteristic curves for the change in
SUV (dSUV) if TRG 1–3 are interpreted as responders, and TRG 4
and 5 as non-responders. The resulting cut off for dSUV is a decrease
in activity of 41 %, yielding a sensitivity, specificity, positive and
negative predictive value and an accuracy of 72, 75, 83, 62 and 74 %,
respectively
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A limitation of the presented data is the retrospective
nature, which makes an accurate identification and corre-
lation of lesions in pathology reports with the FDG PET/
CT images difficult. We were therefore limited to 31
lesions. This also limited the possibility for outcome
analysis; since only 23 patients were included we focused
on the lesion-based analysis only.
Larger studies analyzing the correlation between change
in SUV and histopathological tumor response are desirable,
ideally in a prospective setting with response assessment
scheduled within a standardized timeframe after comple-
tion of neoadjuvant therapy and imaging protocols [22]. In
the present study, the variable time between chemotherapy
and surgery among different patients limits the informative
value of the histopathological response scoring. However,
this was still in accordance with the retrospective manner
and selection of patients with different therapies and time
regimes that were used to predict pathological response
[16]. Also the chosen time frame of 8 weeks between PET
and surgery is within the range of previously published
studies for FDG PET/CT response assessment for HCRC
[18]. A further limitation is that we did not have contrast
enhanced CT-scans. Therefore, morphologic response
assessment was not performed and a comparison of meta-
bolic versus morphologic response not possible.
To strengthen or modify the result of 41 % decrease in
FDG uptake presented in this study, larger cohorts imaged
with strictly defined protocols will be required. However,
these are the first results analyzing the correlation between
FDG decrease and TRG for HCRC and they suggest that
we might need to reevaluate the partial metabolic response
criterion in FDG PET/CT therapy response assessment and
seek individual thresholds for different tumors.
Conclusion
A relative change in FDG activity of more than 41 % can
be a prognostic tool to predict histopathological response to
chemotherapy in HCRC. A relative increase or a low-to-
Fig. 4 51-year-old woman with hepatic metastases of a sigma
carcinoma pT4 N1 M1. a1–3 Extensive FDG active liver metastases in
both lobes in the initial PET/CT (18 June 2009) the lesion in liver
segment II was selected (arrow). (a1) The lesion was well deliniated on
axial PET/CT images (a2), but not well demarcated on axial unenhanced
CT (a3). b1–3 After 8 cycles of FOLFIRI with Avastin (until the 8
October 2009) the SUV uptake decreased completely (dSUV -79 %) in
the second PET (5 November 2009) (b2). c Histopathology of the lesion
in segment II (arrow) revealed extensive fibrosis (95 %) corresponding
to TRG 1 (H&E stain, scale bar 200 lm)
Table 3 TRG versus FDG PET/CT
Cut off for dSUV
(-41 %)
TRG
responding
TRG non-
responding
FDG responding 15 3 18
FDG non-responding 5 8 13
20 11 31
Sensitivity 72 %, Specificity 75 %, Negative predictive value 62 %,
Positive predictive value 83 %
Accuracy 74 %
Ann Nucl Med (2013) 27:177–183 181
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Fig. 5 54-year-old man with hepatic metastases of a colon
carcinoma pT3 N2 M1. a1–3 The initial PET/CT (27 August 2009)
revealed three FDG active liver metastases, the largest in segment IVa
(arrow). b1–3 After 5 doses of FOLFIRI (until 1 December 2009) the
SUV uptake increased (dSUV ?126 %) in the second PET (18
December 2009) (b1–2). c Histopathology revealed almost only vital
tumor cells in the metastasis in segment IVa (95 %) corresponding to
TRG 5 (H&E stain, scale bar 200 lm)
Fig. 6 55-year-old man with hepatic metastases of colon carcinoma
pT3 N2 M1. a1–3 Initial PET/CT (7 August 2009) with five FDG
active liver metastases—the lesion in segment III (arrow) was further
analysed. b1–3 After 6 cycles of FOLFOX with Avastin (until 6
October 2009) the SUV uptake decreased significantly (dSUV
-76 %) (Second PET, 28 October 2009). c1–2 Histopathology of
segment III revealed a mixed pattern, with extensive necrosis
([95 %) in most areas (TRG 2) (c1) but other lesions with mostly
vital tumor cells (c2), therefore resulting in TRG 4 (H&E stain, scale
bar 200 lm)
182 Ann Nucl Med (2013) 27:177–183
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moderate decrease in SUV indicated that hepatic lesions
did not respond to therapy.
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